Hypertension

Since the PCSK9 inhibitors were approved for cholesterol management by the FDA in 2015, they have been frequently compared.

Prevalence of hypertension in HIV-positive persons is not attributed to antiretroviral drug treatment in largest adverse event surveillance study.

The septic shock therapy was approved by the FDA last December. How has it fared in its first year of real-world clinical use?

When compared with enalapril, in patients with acute decompensated heart failure, sacubitril–valsartan led to greater reduction in N-terminal pro–B-type natriuretic peptide (NT-proBNP), and reduced re-hospitalization for heart failure, and was well tolerated.

Ezetimibe 10 mg/day significantly reduced the incidence of atherosclerotic cardiovascular events in elderly patients with high LDL cholesterol compared to control.

In visits with overweight or obese children with high blood pressure, pediatricians either provide no communication about BP or unclear or dismissive statements, unless SBP is ≥120 mmHg.

Though new therapies are still in the distant future, advances in diagnosis may be on the horizon.

Distinguishing pulmonary arterial hypertension in patients is a difficult early diagnosis. But seeking out a combination of unexplained symptoms is a good first step.

Salt sensitivity of blood pressure (SSBP) is still poorly understood. How much do you know about it? Find out, here.

Experts advise that primary care physicians give pause next time they treat a patient with unexplained dyspnea—could it be pulmonary hypertension?